The ADHD market is booming, with an 8.5% CAGR and estimated sales of $13.9 billion in 2024. Despite the growth, the pipeline seems stuck, reformulating longer-release versions of two existing stimulant drugs.
The money will also boost Akili’s expansion into treatments for major depressive disorder and cognitive decline associated with multiple sclerosis and Parkinson’s disease.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Akili Labs has kicked off open enrollment for a clinical trial of its Project EVO video game platform in a quest to secure for 510(k) clearance from the U.S. Food and Drug Administration for its lead indication — attention deficit hyperactivity disorder. The trial is recruiting at least 300 participants aged 8-12 years old who […]
"We want this to stand alongside Adderall and other drugs as a doctor-prescribed treatment," CEO Eddie Martucci said. "Our goal is to make this a true digital medicine."
Whether a baby is born underweight of overweight, it can play a role in the child having ADHD.
Shire will likely continue its pursuit of rare disease acquisitions, as CEO Flemming Ornskov hinted at during its latest earnings call. The Irish pharma giant, known largely for its ADHD pipeline, is now focusing in on a rare disease market.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
A new study led by Dr. Soren Dalsgaard of Aarhus University suggests that people diagnosed with attention deficit hyperactivity disorder are at risk of dying at a younger age than those without the disorder. Usually the deaths are a result of automobile crashes and other accidents, according to the findings published in The Lancet on […]
Pharmaceutical company Neos Therapeutics, Inc. announced Wednesday that it has completed a round of financing totaling $20.6 million for its late-stage pipeline of innovative extended-release (XR) products for Attention-Deficit Hyperactivity Disorder. The financing included investments by Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, […]
Drugs like Adderall are sometimes being abused as stimulants for people who don’t actually have ADHD, especially by college students. But there’s more to the story. Whether it’s overdiagnoses or people not getting access to drugs that can help them, distribution of drugs has created some interesting trends, especially for young women. The Huffington Post […]
According to Centers for Disease Control and Prevention 2011 statistics, 11 percent of children ages 4 to 17 have been diagnosed with ADHD , accounting for 6.4 million cases nationwide. Although a lot of cases are successfully treated with behavioral therapy and stimulant medication, not every patient is so fortunate. For some, it seems, a […]
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
“Sybil,” a 1973 book that featured a woman with what was then known as multiple personality disorder, sold millions of copies. The 1976 television movie version of the story brought in tens of millions of viewers. The hype even transcended the decades when it was made into yet another TV movie in 2007. What was […]
NEW YORK (Reuters Health) – Scant research has been done on the long-term safety of drugs for attention-deficit/hyperactivity disorder (ADHD), a new analysis shows, though millions of American children have been taking them for decades. The U.S. Centers for Disease Control and Prevention estimates that 11 percent of American children between the ages of four […]
Neos Therapeutics is planning to make controlled-release ADHD medicines in liquid and dissolving tablet form, so they’re easier for children to take and last throughout the day. The Grand Prairie, Texas, company just rounded up $15.5 million, according to a SEC filing. The company said in a statement that participating investors included Burrill Life Sciences […]
Antipsychotic medications appear to triple the risk of type 2 diabetes in children and teens, with most of the risk occurring in the first year of administration. A retrospective study of more than 43,000 youths found the same threefold increase, no matter how the data were analyzed, Dr. William V. Bobo and his colleagues reported […]
A Boston-area startup emerged from the depths of stealth mode today touting a $7 million financing round that will help it move toward clinical trials of a drug that would treat attention-deficit/hyperactivity disorder (ADHD) without addictive side effects. EB-1020, Neurovance Inc.’s lead drug candidate for ADHD, acts on three neurotransmitters: norepinephrine, dopamine and serotonin. Other […]